Recent Price Movement and Market Context
Despite the recent surge, Transgene Biotek’s stock remains under pressure over longer time horizons. Year-to-date, the stock has declined by 56.22%, significantly underperforming the Sensex, which has gained 9.12% during the same period. Over the past year, the stock has fallen by 57.89%, contrasting with the Sensex’s 4.89% rise. Even over five years, the stock has declined by 41.83%, while the benchmark index has appreciated by nearly 85%. These figures highlight the challenges the company has faced in maintaining investor confidence over time.
However, the recent price action on 12-Dec marks a reversal from a short-term downtrend. After three consecutive days of declines, the stock’s 9.93% gain indicates renewed buying interes...
Read More





